Which problems affected roughly one-third of the study cohort according to the findings?

• A. Undertreated symptoms, likely adverse effects, drug-drug interactions, and duplication of therapy
• B. Unnecessary therapy
• C. Suboptimal therapy
• D. Financial barriers to access

Answer: (A)

The situation being tested is recognizing medication-related problems that commonly appear in pediatric MTM care. About one-third of the cohort showing problems reflects issues like undertreated symptoms (the current therapy isn’t achieving adequate control), likely adverse effects (safety concerns needing monitoring or change), drug-drug interactions (risks when several medications are used together), and duplication of therapy (two meds providing the same effect, adding risk without benefit). These types of issues are the ones MTM teams focus on to improve safety and effectiveness. While unnecessary therapy, suboptimal therapy, and financial barriers are also important, they are not the set of problems reported as affecting roughly one-third in this finding.